Sites Begin Opening for Enrollment
Enrollment has started in the HEALEY ALS Platform Trial at selected sites, and we expect to add more sites and more potential therapies soon.Read the full announcement
See list of sites
March 25, 2020: HEALEY ALS Platform Trial Updates and April 8th Webinar
As you all are, we too are closely monitoring the impact of COVID-19 on the HEALEY ALS Platform Trial timelines and operations. The bottom line is this: we are committed to beginning the trial as soon and as safely as we can.
January 22, 2020: Sean M. Healey & AMG Center for ALS at Mass General receives “May Proceed” notice for three drugs in first ALS platform trial
The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS)
Merit Cudkowicz, MD, MSc, Director of the Healey Center for ALS, discusses the impact of the “May Proceed” notice from the FDA for three drugs in first ALS platform trial
January 14, 2020: ALS Association makes multi-year commitment to HEALEY ALS Platform Trial
The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
September 18, 2019: Sean M. Healey & AMG Center for ALS at Mass General launches first ALS Platform Trial with 5 promising drugs
The Sean M. Healey & AMG Center at Massachusetts General Hospital will launch the first platform trial for amyotrophic lateral sclerosis (ALS) to accelerate the development of effective and breakthrough treatments for people with ALS.